RT Journal Article
SR Electronic
T1 Long Term Humoral Immunity Decline in Hemodialysis Patients Following SARS-CoV-2 Vaccination
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.01.21265957
DO 10.1101/2021.12.01.21265957
A1 Goggins, Eibhlin
A1 Sharma, Binu
A1 Ma, Jennie Z.
A1 Gautam, Jitendra
A1 Bowman, Brendan
YR 2021
UL http://medrxiv.org/content/early/2021/12/17/2021.12.01.21265957.abstract
AB Dialysis patients are extremely vulnerable to SARS-CoV-2 infection with high rates of hospitalization and mortality rates estimated at 20-30%. In January of 2021, the University of Virginia Dialysis Program initiated a program wide vaccination campaign administering Pfizer BioNTech mRNA SARS-CoV-2 (BNT162b2) vaccine. To characterize the time-dependent decline in humoral immunity, we performed a prospective cohort study measuring serial monthly semi quantitative IgG antibody levels to the SARS-CoV-2 spike protein receptor binding domain in fully vaccinated in-center hemodialysis patients. Measurements were taken beginning at 2 months post full vaccination through 6 months after full vaccination. Early results showed similar seroconversion rates as prior studies with 88% obtaining positive antibody levels. Those with prior infection obtained the highest antibody levels. Over the ensuing months, patient antibody levels declined at an adjusted average rate of 31% per month. At the conclusion of the study, 40% of patients remaining in the cohort possessed either negative or borderline IgG antibody levels. Projecting future antibody levels based on the slopes of antibody level decay suggests 65% of the cohort will progress to borderline or negative antibody levels at 10 months post full vaccination. In summary, we studied long term vaccine response following vaccination with the BNT162b2 mRNA vaccine in hemodialysis patients. Our data adds to the limited pool of data in this patient population and will help to inform the discussion about vaccine booster needs and frequency.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding for this project was provided by the University of Virginia Division of Nephrology / University of Virginia Nephrology Clinical Research Center. No external funding or contributions were provided regarding this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This research proposal was reviewed and approved by the University of Virginia Institutional Review Board for Health Sciences Research (tracking number: HSR 210095)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is not freely available externally. Please contact author if interested in de-identified data set for research purposes